Lead Product(s): PP-OO1
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2020
Panoptes Pharma GmbH has been able to demonstrate that COVID-19 treatment with PP-001 inhibits excessive release of certain cytokines.